FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560758064> ?p ?o ?g. }

• W2560758064 endingPage "1970" @default.
• W2560758064 startingPage "1970" @default.
• W2560758064 abstract "Abstract Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) disorders characterized by ineffective hematopoiesis and cellular dysplasia with high rates of transformation to leukemia. The only cure is hematopoietic stem cell transplant, which is associated with significant morbidity and mortality, thus there is a need to better delineate the pathogenesis of MDS and identify novel targets for treatment. Recent studies suggest that deregulated innate immune signaling, and, in particular, enhanced toll like receptor (TLR) signaling, may contribute to the pathogenesis of MDS. The TLRs are a family of pattern recognition receptors that play a central role in innate immunity. Specifically, TLR2 and its binding partners, TLR1 and TLR6, are markedly elevated in the CD34+ cells of patients with MDS compared to healthy controls (Wei et al, Leukemia 2013). Thus, we hypothesize that enhanced TLR2 signaling may contribute to the pathogenesis of MDS. To elucidate the contribution of TLR2 signaling to MDS, we used a well-characterized mouse model of MDS (mice expressing the NUP98-HOXD13 fusion from the hematopoietic Vav-1 promoter) to determine the effects of loss or gain of TLR2 signaling on disease progression. These NHD13 mice have cytopenias, dysplasia, marrow hypercellularity, and increased apoptosis by 4-7 months of age; transgenic mice die by 14 months of age of leukemia or cytopenias (Lin et al, Blood 2005).Of note, similar to human HSCs, we find increased expression of TLR2 by flow cytometry on the HSCs of NHD13 mice compared to controls. Given the association of enhanced TLR2 signaling with MDS, we predicted that loss of TLR2 would improve outcomes in NHD13 mice. To this end, these mice were crossed to Tlr2-/- mice to generate 4 groups: NHD13+;Tlr2-/-; NHD13+;Tlr2+/+, NHD13-;Tlr2-/- and NHD13-;Tlr2+/+. Surprisingly, loss of TLR2 is associated with significantly worse survival with a median survival of 313 days for NHD13+;Tlr2-/-, and 367 days for NHD13+;Tlr2+/+(p=0.01; with the majority of mice dying from leukemia); and loss of TLR2 did not improve cytopenias. Ongoing experiments are aimed at determining the effects of TLR2 loss on HSC cycling, apoptosis, and function in the NHD13 mice and their wild-type (WT) sibling controls. Conversely, we are asking how stimulation of TLR2 affects disease by treating NHD13 mice chronically with a TLR1/2 agonist (PAM3CSK4) or a TLR2/6 agonist (PAM2CSK4) or water control. NHD13 mice receiving PAM2CSK4 had elevated white blood cell and hemoglobin counts after five months as compared to mice receiving PAM3CSK4 and control mice, while mice receiving PAM3CSK4 demonstrated a higher incidence of thrombocytopenia, suggesting that TLR2 signaling may contribute to cytopenias. Strikingly, however, we found that treatment with the TLR2/6 agonist (PAM2CSK4) significantly (p < 0.0001) accelerates the time to leukemia and death (but not the TLR1/2 agonist, PAM3CSK4), with deaths occurring as early as 70 days of life, mostly from leukemia. After four months of treatment, 100% of control and 93% of PAM3CSK4 treated NHD13 mice were alive, while only 37.5% of PAM2CSK4 treated NHD13 mice were alive (p= 0.0002). This raises the intriguing possibility that there are heterodimer-specific effects of TLR2 signaling on premalignant HSCs. Historically, the association of TLR2 with TLR1 versus TLR6 was thought to expand the ligand spectrum without altering downstream signaling (Farhat et al, J Leuk Biol 2008), however recent data (and our own findings) suggest that there may be heterodimer-specific differences (Rolf et al, Euro J of Immunology 2015). Furthermore, while expression of TLR2 itself correlates with low-risk disease and longer survival, high expression of TLR6 is associated with higher-risk disease and increased marrow blasts (Wei et al, Leukemia 2013). We are currently exploring the mechanisms behind the heterodimer-specific effects of TLR2 signaling on leukemogenesis and survival in the NHD13 mice by elucidating the effects of PAM3CSK4 versus PAM2CSK4 on HSC cycling, apoptosis, and function, as well as determining the downstream signaling pathways (utilizing mass cytometry) and target genes that are uniquely activated by the different agonists. Ultimately, an understanding of TLR1/2 versus TLR2/6 stimulation effects on WT and premalignant HSCs is critical to the development of targeted therapies toward this pathway. Disclosures No relevant conflicts of interest to declare." @default.
• W2560758064 created "2016-12-16" @default.
• W2560758064 creator A5018151522 @default.
• W2560758064 creator A5023805918 @default.
• W2560758064 creator A5053436400 @default.
• W2560758064 creator A5057334251 @default.
• W2560758064 creator A5062528180 @default.
• W2560758064 creator A5071450878 @default.
• W2560758064 creator A5073441208 @default.
• W2560758064 creator A5083747044 @default.
• W2560758064 date "2016-12-02" @default.
• W2560758064 modified "2023-09-26" @default.
• W2560758064 title "Toll like Receptor 2/6 but Not 1/2 Signaling Promotes Leukemogenesis in a Mouse Model of Myelodysplastic Syndrome" @default.
• W2560758064 doi "https://doi.org/10.1182/blood.v128.22.1970.1970" @default.
• W2560758064 hasPublicationYear "2016" @default.
• W2560758064 type Work @default.
• W2560758064 sameAs 2560758064 @default.
• W2560758064 citedByCount "1" @default.
• W2560758064 countsByYear W25607580642017 @default.
• W2560758064 crossrefType "journal-article" @default.
• W2560758064 hasAuthorship W2560758064A5018151522 @default.
• W2560758064 hasAuthorship W2560758064A5023805918 @default.
• W2560758064 hasAuthorship W2560758064A5053436400 @default.
• W2560758064 hasAuthorship W2560758064A5057334251 @default.
• W2560758064 hasAuthorship W2560758064A5062528180 @default.
• W2560758064 hasAuthorship W2560758064A5071450878 @default.
• W2560758064 hasAuthorship W2560758064A5073441208 @default.
• W2560758064 hasAuthorship W2560758064A5083747044 @default.
• W2560758064 hasConcept C109159458 @default.
• W2560758064 hasConcept C136449434 @default.
• W2560758064 hasConcept C203014093 @default.
• W2560758064 hasConcept C2776709828 @default.
• W2560758064 hasConcept C2778461978 @default.
• W2560758064 hasConcept C2780007613 @default.
• W2560758064 hasConcept C2780817109 @default.
• W2560758064 hasConcept C2780942790 @default.
• W2560758064 hasConcept C2781236682 @default.
• W2560758064 hasConcept C28328180 @default.
• W2560758064 hasConcept C502942594 @default.
• W2560758064 hasConcept C86803240 @default.
• W2560758064 hasConcept C8891405 @default.
• W2560758064 hasConcept C95444343 @default.
• W2560758064 hasConceptScore W2560758064C109159458 @default.
• W2560758064 hasConceptScore W2560758064C136449434 @default.
• W2560758064 hasConceptScore W2560758064C203014093 @default.
• W2560758064 hasConceptScore W2560758064C2776709828 @default.
• W2560758064 hasConceptScore W2560758064C2778461978 @default.
• W2560758064 hasConceptScore W2560758064C2780007613 @default.
• W2560758064 hasConceptScore W2560758064C2780817109 @default.
• W2560758064 hasConceptScore W2560758064C2780942790 @default.
• W2560758064 hasConceptScore W2560758064C2781236682 @default.
• W2560758064 hasConceptScore W2560758064C28328180 @default.
• W2560758064 hasConceptScore W2560758064C502942594 @default.
• W2560758064 hasConceptScore W2560758064C86803240 @default.
• W2560758064 hasConceptScore W2560758064C8891405 @default.
• W2560758064 hasConceptScore W2560758064C95444343 @default.
• W2560758064 hasIssue "22" @default.
• W2560758064 hasLocation W25607580641 @default.
• W2560758064 hasOpenAccess W2560758064 @default.
• W2560758064 hasPrimaryLocation W25607580641 @default.
• W2560758064 hasRelatedWork W1517608889 @default.
• W2560758064 hasRelatedWork W1914689199 @default.
• W2560758064 hasRelatedWork W1963802005 @default.
• W2560758064 hasRelatedWork W1981608517 @default.
• W2560758064 hasRelatedWork W2103675344 @default.
• W2560758064 hasRelatedWork W2152163440 @default.
• W2560758064 hasRelatedWork W2792679014 @default.
• W2560758064 hasRelatedWork W3209460650 @default.
• W2560758064 hasRelatedWork W4210379329 @default.
• W2560758064 hasRelatedWork W4296981756 @default.
• W2560758064 hasVolume "128" @default.
• W2560758064 isParatext "false" @default.
• W2560758064 isRetracted "false" @default.
• W2560758064 magId "2560758064" @default.
• W2560758064 workType "article" @default.